Reported by Seeking Alpha · seekingalpha.com · August 20, 2026
Amylyx Pharmaceuticals (AMLX) announced the pricing of an upsized underwritten public offering of 14.09M shares of common stock at $35.50 per share. The company also granted underwriters a 30-day option to buy up to an additional 2.11M shares.
What to watch: AMLX (AMLX) is involved in M&A activity valued around $35.50 — deal terms and financing structure matter more than the headline here.
Market reaction today: $AMLX -1.32%
Tone and severity are deterministic keyword classification — not a prediction, a member vote, or a recommendation. Figures are extracted from the headline as published. Wook does not republish Seeking Alpha's reporting.
No one has weighed in yet. Start the discussion on this story.
Headline and link are attributed to Seeking Alpha. Wook of Wall Street is an independent research tool and is not affiliated with Seeking Alpha. Nothing here is financial advice or a recommendation — research and educational content only.